Rogaine (Minoxidil)

What is Rogaine or Regaine?

These are brand names used for topical minoxidil in different markets. This page describes Spain’s Regaine 50 mg/g cutaneous foam for adult men and separately identifies UK Regaine for Women Once a Day 5% foam. It does not establish the authorisation or availability of a Spanish women’s product.

Minoxidil can stimulate and prolong the hair-growth phase; its exact mechanism is not fully understood. It does not reduce DHT like finasteride. Neither mechanism guarantees a response.

Who is it for?

Do not use either named foam if you are allergic to minoxidil or any of its ingredients.

The Spanish men’s foam treats androgenetic alopecia in men from 18 years. It is not for women or children. Sudden or patchy loss, an unknown cause or no family history requires assessment; these are not the named product’s indication.

The UK women’s foam is for female pattern hair loss at ages 18–65. It is not for men, childbirth-related hair loss or unexplained loss. Its contraindications include treated or untreated hypertension, scalp abnormalities, a shaved scalp, allergy to a component, and use of occlusive dressings or other topical medicines. Do not use it during pregnancy or breastfeeding.

Product-specific application

These are foam quantities, not millilitres of a solution. A 50 mg/g concentration equals 5% by weight. Do not apply a universal twice-daily schedule to women’s products. No solution or oral-minoxidil regimen is supplied here.

Apply only to completely dry, healthy scalp and hair, covering the affected area with the total stated dose. Wash hands afterwards. Do not apply elsewhere or to inflamed, infected, irritated or painful scalp. More product or more frequent application does not improve results.

Avoid eyes, mouth and other sensitive surfaces; rinse accidental contact with plenty of cool water. Avoid transferring the product to the face or to children, including skin contact with treated areas. Keep it out of children’s reach: accidental swallowing can cause serious heart effects. Follow the exact pack’s drying and flammable-container precautions.

Initial shedding and continued use

Increased shedding can begin 2–6 weeks after starting and usually subsides within a couple of weeks. It is not unconditional reassurance of success. The Spanish label says to stop and consult if shedding persists; the UK women’s label explicitly says to stop and consult if shedding lasts more than 2 weeks.

If regrowth occurs, ongoing appropriate use is needed to maintain it; hair loss resumes after stopping. Do not ignore stop criteria or adverse effects merely to preserve regrowth.

Adverse effects

Frequencies differ between the two labels. In the Spanish men’s foam label, headache, itching, dermatitis, rash and unwanted non-scalp hair are common; dizziness, nausea and peripheral swelling are uncommon; palpitations, tachycardia and chest pain are rare. Hypotension, severe allergic reactions and application-site reactions have unknown frequency.

The UK women’s foam label instead classifies headache as very common and chest pain and peripheral swelling as common. This difference is not proof that one product is safer; each label draws on its stated trial and post-marketing evidence. Do not copy a frequency from one product to the other.

Stop minoxidil and seek medical assessment for low blood pressure, chest pain, a rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, swollen hands or feet, persistent scalp redness/irritation or any new unexpected symptom. Severe chest pain, breathing difficulty or face/throat swelling requires urgent care. Do not drive if dizzy or affected by low blood pressure.

Interactions and alternatives

The named products must not be used with other topical scalp medicines, including corticosteroids, tretinoin or dithranol, because absorption can change. This combination restriction is not an instruction to stop another prescribed medicine yourself. Contact the prescriber to review the regimen.

Known cardiovascular disease or arrhythmia requires advice before use. Mention blood-pressure medicines, kidney/liver disease and all scalp conditions.

Oral finasteride, such as Propecia 1 mg, has different restrictions and mood/sexual warnings. A restriction on topical scalp combinations is not automatically an instruction about oral finasteride; the latter combination still requires individual assessment, and this page does not promise additive benefit. Oral minoxidil is also a different treatment: a prescription requirement is not proof of an authorised alopecia indication.

Independent assessment

Prescrivia is a technology intermediary connecting patients with independent doctors. It does not prescribe, employ doctors or sell medicines. Provide hair-loss history, conditions and medication for assessment. Any prescription and pharmacy dispensing depend on clinical suitability, the exact product, applicable rules and availability. No prescription, supply or hair-growth outcome is guaranteed.

In Spain, distance sale of prescription medicines is prohibited under Article 3.5 of Royal Legislative Decree 1/2015. An online assessment does not remove this restriction. Dispensing and access depend on the exact product and applicable national rules.

Sources

• AEMPS CIMA: Regaine 50 mg/g foam, sections 2, 4.1–4.8 and 5.1–5.2.
• McNeil: UK Regaine for Women Once a Day 5% foam, sections 2, 4.1–4.8 and 5.1–5.2.

This selected information does not replace the exact leaflet or individual medical advice.